Skip to main content
The Actuary: The magazine of the Institute and Faculty of Actuaries - return to the homepage Logo of The Actuary website
  • Search
  • Visit The Actuary Magazine on Facebook
  • Visit The Actuary Magazine on LinkedIn
  • Visit @TheActuaryMag on Twitter
Visit the website of the Institute and Faculty of Actuaries Logo of the Institute and Faculty of Actuaries

Main navigation

  • News
  • Features
    • General Features
    • Interviews
    • Students
    • Opinion
  • Topics
  • Knowledge
    • Business Skills
    • Careers
    • Events
    • Predictions by The Actuary
    • Whitepapers
    • Moody's - Climate Risk Insurers series
    • Webinars
    • Podcasts
  • Jobs
  • IFoA
    • CEO Comment
    • IFoA News
    • People & Social News
    • President Comment
  • Archive
Quick links:
  • Home
  • Sections
  • News

COVID-19 could trigger 'sharp rise' in antimicrobial resistance

Open-access content Wednesday 10th June 2020

iStock-530809521.jpg

The coronavirus pandemic could lead to a “sharp rise” in antimicrobial resistance due to the widespread use of antibiotics as treatments, microbiologists from Queen's University Belfast have warned.

In a new paper, the scientists highlight how nearly all severe COVID-19 patients are being treated with broad-spectrum antibiotics, which not only may have limited results, but are also associated with higher mortality.

They also warn that potentially fatal bacterial respiratory infections may arise subsequently or coincidentally from hospital stays or from therapies given to treat coronavirus patients.

This comes after the World Health Organization (WHO) recently revealed that a record number of countries are recording "disturbing" rates of antimicrobial resistance.

“Our research suggests that bacterial infection alongside the virus is likely to make the COVID-19 worse, although we don’t yet know the true extent,” said Dr Connor Bamford, virologist at the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s University.

“The rise of antimicrobial resistance in bacteria means this situation is harder to treat. It is clear that we will need new drugs that take into consideration both the virus and the bacteria.”

The paper explains how clinical data, as well as postmortem analysis of tissues from COVID-19 patients, already indicate the presence of bacterial co-infections in COVID-19 patients.

These may worsen the clinical outcome and the severity of COVID-19 in a patient, increasing the risk of death.

The study also highlights how SARS-CoV-2 and bacteria in the lungs may affect each other’s ability to cause damage, and with the immune response to the virus being different when bacteria are present, the clinical outcome and the severity of COVID-19 in a patient could worsen. 

Moreover, it outlines how gut microbiota could also be disrupted in severe COVID-19 patients, which may affect disease outcomes, including predisposition to secondary bacterial infections of the lung.

“It is critical that co-infections should not be underestimated and instead be part of the plan to limit the global burden of morbidity and mortality during the COVID-19 pandemic and beyond,” said professor José Bengoechea, director of the Wellcome-Wolfson Institute for Experimental Medicine.

“We hope that our research exploring the role of bacterial and SARS-CoV-2 co-infections will result in the improved health of COVID-19 patients and possibly even save lives.”

 

Author: Chris Seekings

Image credit: iStock

 

Also filed in
News
Topics
Risk & ERM
Health care
Global

You might also like...

Share
  • Twitter
  • Facebook
  • Linked in
  • Mail
  • Print

Latest Jobs

Risk Actuary - General Insurance

London (Greater)
£60,000 - £85,000
Reference
145934

Project Actuary - Life Insurance

Midlands
£60,000 - £110,000
Reference
145933

Model Validation Actuary

London (Greater)
£60k - £80k
Reference
145932
See all jobs »
 
 

Today's top reads

 
 

Sign up to our newsletter

News, jobs and updates

Sign up

Subscribe to The Actuary

Receive the print edition straight to your door

Subscribe
Spread-iPad-slantB-june.png

Topics

  • Data Science
  • Investment
  • Risk & ERM
  • Pensions
  • Environment
  • Soft skills
  • General Insurance
  • Regulation Standards
  • Health care
  • Technology
  • Reinsurance
  • Global
  • Life insurance
​
FOLLOW US
The Actuary on LinkedIn
@TheActuaryMag on Twitter
Facebook: The Actuary Magazine
CONTACT US
The Actuary
Tel: (+44) 020 7880 6200
​

IFoA

About IFoA
Become an actuary
IFoA Events
About membership

Information

Privacy Policy
Terms & Conditions
Cookie Policy
Think Green

Get in touch

Contact us
Advertise with us
Subscribe to The Actuary Magazine
Contribute

The Actuary Jobs

Actuarial job search
Pensions jobs
General insurance jobs
Solvency II jobs

© 2023 The Actuary. The Actuary is published on behalf of the Institute and Faculty of Actuaries by Redactive Publishing Limited. All rights reserved. Reproduction of any part is not allowed without written permission.

Redactive Media Group Ltd, 71-75 Shelton Street, London WC2H 9JQ